Lindsey Seidlitz
is a Deputy Vice President, Policy and Research at the Pharmaceutical Research and Manufacturers of America. At PhRMA, Lindsey focuses on policy analysis and developing research on a range of issues aimed towards supporting an environment for innovation. Her work seeks to further policymakers and the public’s understanding of the value that new medicines provide to patients and society, the role that medicines play in making our health care system more sustainable, and the dynamics influencing the way medicines compete in certain markets and therapeutic areas. Lindsey holds a BA in Political Science from the University of Southern California and a Masters of Public Policy from Georgetown University.
PBMs, not patents, are blocking access to lower-cost medicines
Biosimilars continue to drive market competition and increase savings for seniors
Biosimilars drive savings, but the IRA undermines their development
New report shows high-impact R&D happens after cancer medicines are first approved
New resource underscores the importance of small molecule medicines
Study finds hepatitis C cure saved Medicaid $15 billion
New paper: Addressing the growing crisis of mental health and substance use disorders
Lindsey Seidlitz